Selecta Biosciences (SELB) 15.01 $SELB Selecta
Post# of 273240
Posted On: 09/25/2016 11:09:24 PM
Selecta Biosciences (SELB) 15.01 $SELB
Selecta Biosciences Announces Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Aug 09, 6:00AM CDT
-- Demonstrated clinical activity in Phase 1 program of SEL-212
SELB: 15.01 (+0.94)
Selecta Biosciences to Present at Canaccord Genuity Growth Conference
GlobeNewswire - Thu Aug 04, 6:00AM CDT
Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, today announced that Kei Kishimoto, Ph.D., CSO, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016, at 9:30 am EDT at the InterContinental in Boston.
SELB: 15.01 (+0.94)
Selecta Biosciences to Report Second Quarter 2016 Financial Results on Tuesday, August 9
GlobeNewswire - Tue Aug 02, 3:01PM CDT
Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, will host a conference call on Tuesday, August 9, 2016, at 8:30 a.m., Eastern Time. During the call, management will review the company's second quarter 2016 financial results and provide a corporate update.
SELB: 15.01 (+0.94)
Selecta Biosciences Announces Publication in Nature Nanotechnology Describing Novel Approach for Improving the Efficacy and Safety Profile of Biologic Drugs
GlobeNewswire - Mon Aug 01, 11:53AM CDT
-- Published results from preclinical studies show the potential of Selecta's proprietary SVP-Rapamycin (SEL-110) immune therapy to improve the efficacy and safety of biologic therapeutics
SELB: 15.01 (+0.94)
Selecta Biosciences Appoints Timothy C. Barabe to Board of Directors
GlobeNewswire - Mon Aug 01, 6:00AM CDT
Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, today announced the election of Timothy C. Barabe to the company's Board of Directors. Most recently serving as chief financial officer and executive vice president at Affymetrix Inc., Mr. Barabe has extensive experience in the life sciences industry, having held a broad range of financial and strategic roles.
SELB: 15.01 (+0.94), AFFX: 14.01 (+0.02)
Selecta Biosciences Announces Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Aug 09, 6:00AM CDT
-- Demonstrated clinical activity in Phase 1 program of SEL-212
SELB: 15.01 (+0.94)
Selecta Biosciences to Present at Canaccord Genuity Growth Conference
GlobeNewswire - Thu Aug 04, 6:00AM CDT
Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, today announced that Kei Kishimoto, Ph.D., CSO, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016, at 9:30 am EDT at the InterContinental in Boston.
SELB: 15.01 (+0.94)
Selecta Biosciences to Report Second Quarter 2016 Financial Results on Tuesday, August 9
GlobeNewswire - Tue Aug 02, 3:01PM CDT
Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, will host a conference call on Tuesday, August 9, 2016, at 8:30 a.m., Eastern Time. During the call, management will review the company's second quarter 2016 financial results and provide a corporate update.
SELB: 15.01 (+0.94)
Selecta Biosciences Announces Publication in Nature Nanotechnology Describing Novel Approach for Improving the Efficacy and Safety Profile of Biologic Drugs
GlobeNewswire - Mon Aug 01, 11:53AM CDT
-- Published results from preclinical studies show the potential of Selecta's proprietary SVP-Rapamycin (SEL-110) immune therapy to improve the efficacy and safety of biologic therapeutics
SELB: 15.01 (+0.94)
Selecta Biosciences Appoints Timothy C. Barabe to Board of Directors
GlobeNewswire - Mon Aug 01, 6:00AM CDT
Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, today announced the election of Timothy C. Barabe to the company's Board of Directors. Most recently serving as chief financial officer and executive vice president at Affymetrix Inc., Mr. Barabe has extensive experience in the life sciences industry, having held a broad range of financial and strategic roles.
SELB: 15.01 (+0.94), AFFX: 14.01 (+0.02)
(0)
(0)Scroll down for more posts ▼